KHRR 296-299 AAAA T103N

alteplase variant; has additional glycosylation site & tetra-alanine substitution in the alteplase protease domain; has resistance to fast acting inhibitor PAI-1; fibrin specific

Also Known As:

T103N, KHRR 296-299 AAAA; KHRR 296-299 AAAA; Kt-PA variant; t-PA variant

Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1.	Coronary Thrombosis 04/01/1992 - "We evaluated in a canine model of coronary thrombosis which is known to elicit reocclusion, whether an increased single i.v. bolus dose or two boli of the novel t-PA variant BM 06.022 improved coronary blood flow after reperfusion compared to i.v. injection of a standard single dose of BM 06.022. "
2.	Thrombosis (Thrombus) 02/15/1994 - "However, lysis of the model platelet-rich thrombus did proceed some 30% more quickly when treated with a plasminogen activator inhibitor (PAI)-resistant t-PA variant. " 08/02/1993 - "Potency of the variants relative to t-PA on whole blood clots ranged from 0.9 (T103N, KHRR 296-299 AAAA) to 1.7 (T103N). "

Related Drugs and Biologics

1.	reteplase
2.	Plasminogen Inactivators
3.	T103N